Pyxis Oncology, Inc.
- Jurisdiction
United States - ISIN
US7473241013 (PYXS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Read full profile
Stock price
Fundamentals
- Net revenue
€5.34M - Gross margin
72.7% - EBIT
-€91.41M - EBIT margin
-1,711.5% - Net income
-€82.66M - Net margin
-1,547.5%
Statement period: - (published )
Dividends
No dividend payouts
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |